BR0304659A - Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes - Google Patents

Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes

Info

Publication number
BR0304659A
BR0304659A BR0304659-1A BR0304659A BR0304659A BR 0304659 A BR0304659 A BR 0304659A BR 0304659 A BR0304659 A BR 0304659A BR 0304659 A BR0304659 A BR 0304659A
Authority
BR
Brazil
Prior art keywords
domain
fusion protein
thrombomodulin
anticoagulants
tissue factor
Prior art date
Application number
BR0304659-1A
Other languages
English (en)
Inventor
David Light
Kirk Mclean
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0304659(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0304659A publication Critical patent/BR0304659A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

"FATOR DE TECIDO DE PROTEìNAS DE FUSãO ALVOS TROMBOMODULINA COMO ANTICOAGULANTES". Esta invenção refere-se a novas proteínas de fusão que são compreendidas por uma proteína alvo que se liga a fator de tecido (TF), que é ligado operacionalmente ao domínio trombomodulina (TM) EGF456 isoladamente ou em combinação com pelo menos outro domínio TM selecionado do grupo consistindo no domínio da regiao hidrofóbica N-terminal, do domínio EGF123, do laço de interdomínio entre EGF3 e EGF4, e do domínio Oglicosilado rico em Ser/Thr, ou análogos, fragmentos, derivados ou variantes dos mesmos. A proteína de fusão se liga ao sítio da lesão e evita a iniciação da trombose. A proteína de fusão pode ser utilizada para tratar uma diversidade de condições trombóticas incluindo, mas não limitadas a, trombose de veia profunda, coagulação intravascular disseminada, e síndrome coronária aguda.
BR0304659-1A 2002-05-01 2003-04-30 Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes BR0304659A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013522 WO2003092602A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Publications (1)

Publication Number Publication Date
BR0304659A true BR0304659A (pt) 2004-09-21

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0304659-1A BR0304659A (pt) 2002-05-01 2003-04-30 Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes
BR0304660-5A BR0304660A (pt) 2002-05-01 2003-04-30 Anticorpos direcionados a fator de tecido como anticoagulantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0304660-5A BR0304660A (pt) 2002-05-01 2003-04-30 Anticorpos direcionados a fator de tecido como anticoagulantes

Country Status (29)

Country Link
US (3) US7250168B2 (pt)
EP (2) EP1549341B1 (pt)
JP (2) JP4460443B2 (pt)
KR (2) KR101013697B1 (pt)
CN (2) CN100412090C (pt)
AR (1) AR039515A1 (pt)
AT (2) ATE427121T1 (pt)
AU (2) AU2003225255B2 (pt)
BR (2) BR0304659A (pt)
CA (2) CA2483910A1 (pt)
CR (1) CR7584A (pt)
DE (2) DE60326970D1 (pt)
DK (2) DK1549341T3 (pt)
EC (2) ECSP045468A (pt)
ES (2) ES2323056T3 (pt)
HK (1) HK1080372A1 (pt)
IL (3) IL164733A0 (pt)
MX (2) MXPA04010851A (pt)
NO (2) NO20035849L (pt)
NZ (2) NZ536242A (pt)
PE (1) PE20040597A1 (pt)
PL (2) PL373945A1 (pt)
PT (2) PT1503785E (pt)
RS (2) RS104504A (pt)
RU (2) RU2320366C2 (pt)
TW (1) TWI343388B (pt)
UA (2) UA81114C2 (pt)
WO (2) WO2003092602A2 (pt)
ZA (2) ZA200409692B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1188830T3 (da) * 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
AU9630501A (en) 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
JP4460443B2 (ja) * 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CN103045601B (zh) 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
CN101189334B (zh) 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
CN101466400B (zh) * 2006-04-07 2014-06-25 诺沃-诺迪斯克保健股份有限公司 共价凝血因子ⅶ-组织因子复合物
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
US20100152106A1 (en) * 2006-10-06 2010-06-17 Asahi Kasei Pharma Corporation Agent for therapy and/or improvement of disseminated intravascular coagulation
US9649499B2 (en) 2007-03-28 2017-05-16 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
CA2700293A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
WO2009086552A1 (en) * 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US9644197B2 (en) * 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
CA2807749C (en) 2010-08-05 2023-02-28 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
KR20190083355A (ko) * 2016-11-16 2019-07-11 바이엘 헬쓰케어 엘엘씨 적혈구 표적화된 인자 viii 및 이를 사용하는 방법
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
US20210318338A1 (en) * 2018-10-04 2021-10-14 Thrombosis And Coagulation Ab Method for the determination of protein s levels
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑
CN114686444A (zh) * 2020-12-31 2022-07-01 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
KR920701459A (ko) * 1989-02-17 1992-08-11 코돈 트롬보모듈린의 가용성 유사체
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ES2364266T3 (es) * 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
AU2001250814B2 (en) * 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
EP1465998A2 (en) 2002-01-08 2004-10-13 Bayer HealthCare AG Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
JP4460443B2 (ja) 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
IL164733A (en) 2011-05-31
WO2003092602A3 (en) 2004-08-26
CN1665526A (zh) 2005-09-07
JP2005532045A (ja) 2005-10-27
ATE427121T1 (de) 2009-04-15
RS104504A (sr) 2007-02-05
EP1503785A4 (en) 2007-02-14
ECSP045467A (es) 2005-01-28
UA81114C2 (en) 2007-12-10
KR20050045944A (ko) 2005-05-17
US20040063632A1 (en) 2004-04-01
PE20040597A1 (es) 2004-10-06
RU2004135306A (ru) 2005-07-10
EP1549341B1 (en) 2009-04-01
PT1549341E (pt) 2009-05-29
AU2003225255A1 (en) 2003-11-17
CR7584A (es) 2006-05-30
CN100563709C (zh) 2009-12-02
PT1503785E (pt) 2011-01-17
ECSP045468A (es) 2005-01-28
PL373945A1 (en) 2005-09-19
IL164733A0 (en) 2005-12-18
JP2005538046A (ja) 2005-12-15
EP1503785A2 (en) 2005-02-09
ZA200409692B (en) 2006-07-26
NZ536243A (en) 2006-06-30
AR039515A1 (es) 2005-02-23
DE60326970D1 (de) 2009-05-14
RS102404A (sr) 2006-12-15
AU2003225256A1 (en) 2003-11-17
EP1503785B1 (en) 2010-10-13
KR101080587B1 (ko) 2011-11-04
NO20035848L (no) 2004-02-27
ATE484524T1 (de) 2010-10-15
IL164732A0 (en) 2005-12-18
KR20050045945A (ko) 2005-05-17
TWI343388B (en) 2011-06-11
US7250168B2 (en) 2007-07-31
JP4567437B2 (ja) 2010-10-20
ES2354419T3 (es) 2011-03-14
PL210582B1 (pl) 2012-02-29
MXPA04010851A (es) 2005-02-14
WO2003093422A2 (en) 2003-11-13
EP1549341A4 (en) 2006-10-18
HK1080372A1 (zh) 2006-04-28
UA85996C2 (ru) 2009-03-25
DK1549341T3 (da) 2009-07-06
RU2345789C2 (ru) 2009-02-10
RU2320366C2 (ru) 2008-03-27
DE60334538D1 (de) 2010-11-25
NO20035849L (no) 2004-02-27
CN1665534A (zh) 2005-09-07
EP1549341A2 (en) 2005-07-06
WO2003092602A2 (en) 2003-11-13
CA2483909A1 (en) 2003-11-13
KR101013697B1 (ko) 2011-02-10
JP4460443B2 (ja) 2010-05-12
TW200307043A (en) 2003-12-01
US20080019985A1 (en) 2008-01-24
PL373960A1 (en) 2005-09-19
AU2003225256B2 (en) 2009-06-04
BR0304660A (pt) 2005-06-07
ES2323056T3 (es) 2009-07-06
US7622122B2 (en) 2009-11-24
ZA200409694B (en) 2006-02-22
CN100412090C (zh) 2008-08-20
CA2483910A1 (en) 2003-11-13
US7622457B2 (en) 2009-11-24
US20080020965A1 (en) 2008-01-24
DK1503785T3 (da) 2011-02-07
RU2004135308A (ru) 2005-08-10
MXPA04010795A (es) 2005-03-07
WO2003093422A3 (en) 2004-07-15
AU2003225255B2 (en) 2008-07-31
NZ536242A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
BR0304659A (pt) Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes
DK0975672T3 (da) Antistoffer til inhibition af blodkoagulation og fremgangsmåder til anvendelse heraf
DE60238782D1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
BR0206644A (pt) Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
EA200300845A1 (ru) Модифицированные антитела и способы применения
BR0215218A (pt) Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
DE69831566T2 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
NO20033839L (no) Transplantatrejeksjonssuppressorer
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
MEP26808A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
ES2188202T3 (es) Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
JP2005538046A5 (pt)
EA200100925A1 (ru) Применение глицинбетаина в качестве антитромботического средства
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
ECSP003707A (es) Diazepanes
BRPI0410844A (pt) fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
NO20026286D0 (no) Nye peptider
ATE480552T1 (de) Stq-peptide
DK1222854T3 (da) Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
BRPI0411353A (pt) moléculas de corina modificadas tendo seqüências de ativação substitutas e aplicações das mesmas
BR0213953A (pt) Composição farmacêutica, kit de partes, uso de fator vii ou um polipeptìdeo relacionado com fator vii em combinação com um fator v ou um polipeptìdeo relacionado com fator v, uso de uma composição, métodos para tratar episódios de sangramento em um sujeito, para reduzir o tempo de coagulação, para intensificar hemóstase, para prolongar o tempo de lise de coágulos em um sujeito, e para incrementar a resistência do coágulo em um sujeito, kit contendo um tratamento para episódios de sangramento
Izumi et al. Hemostatic efficacy of a recombinant thrombin-coated polyglycolic acid sheet coupled with liquid fibrinogen, evaluated in a canine model of pulmonary arterial hemorrhage
ATE412903T1 (de) Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.